Focus: Novartis is a globally diversified pharmaceutical giant with 78,000 employees headquartered in Basel, Switzerland, operating across oncology, immunology, neuroscience, cardiovascular, and ophthalmology. The company is a major player in small molecules, vaccines, and biologics with significant revenue concentration in peak-stage products.
Profile data last refreshed Yesterday · AI intelligence enriched 2mo ago
Hot — 1178 jobs added in 30d
Net +569 (1178 new, 609 removed). Aggressive expansion phase.
5 recent layoff filings (12 mo) — 424 affected
Source: state DOL filings via Big Local News
A stable Big Pharma with strong diversification and pipeline depth, but near-term patent cliff pressures and revenue concentration warrant caution on long-term role security.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Flagship cardiovascular product generating 54% of company revenue; patent protection extends to 2036 but faces significant generic erosion risk post-LOE.
Help build intelligence for Novartis
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Novartis's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Second-tier immunology product losing exclusivity in 14 months; represents the most immediate commercial and organizational threat to career stability.
Oncology franchise pillar with extended protection; demonstrates Novartis's strength in kinase inhibitor space.
CDK4/6 inhibitor with strong growth trajectory and extended patent protection; core oncology franchise driver.
450 discontinued, 226 duplicate formulations not shown
+50 more products with revenue data
Novartis RemIND data show Rhapsido potential for CIndU - The Pharma Letter
Novartis RemIND data show Rhapsido potential for CIndU The Pharma Letter
Novartis Pharma AG - Via Ritzau
Novartis Pharma AG Via Ritzau
Novartis' phase 1/2 win tees up regulatory talks about dystrophy drug from $12B Avidity takeover - Fierce Biotech
Novartis' phase 1/2 win tees up regulatory talks about dystrophy drug from $12B Avidity takeover Fierce Biotech
Novartis says rare muscle disease drug shows promise in early trial - Reuters
Novartis says rare muscle disease drug shows promise in early trial Reuters
Novartis AG Stock (NVS) Moved Up by 4.20% on Jun 11: What Investors Need To Know - TradingKey
Novartis AG Stock (NVS) Moved Up by 4.20% on Jun 11: What Investors Need To Know TradingKey
Novartis Reports Positive Data for Neuromuscular Disorder Drug - Yahoo Finance
Novartis Reports Positive Data for Neuromuscular Disorder Drug Yahoo Finance
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Source: state DOL filings, aggregated via Big Local News
Recent peer-reviewed publications with author affiliations at this company
+204 more products
Recent restructuring and spin-off activities create near-term role instability; combined with PROMACTA cliff, expect additional realignment announcements in 2025–2026.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo